These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28251966)

  • 1. [Scanning for KRAS, NRAS, BRAF, and PIK3CA mutations by DNA melting analysis with TaqMan probes].
    Botezatu IV; Panchuk IO; Stroganova AM; Senderovich AI; Kondratova VN; Shelepov VP; Lichtenstein AV
    Mol Biol (Mosk); 2017; 51(1):50-58. PubMed ID: 28251966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
    Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
    J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR.
    Nagakubo Y; Hirotsu Y; Amemiya K; Oyama T; Mochizuki H; Omata M
    BMC Med Genomics; 2019 Nov; 12(1):162. PubMed ID: 31711486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combined detection of KRAS, NRAS, BRAF and PIK3CA mutations in the plasma and tumor tissues of colorectal cancer patients].
    Liu XN; Tian Z; Wei XF; Wang Q; Zhang JX; Jin MS; Duan XM
    Zhonghua Bing Li Xue Za Zhi; 2019 May; 48(5):373-377. PubMed ID: 31104677
    [No Abstract]   [Full Text] [Related]  

  • 5. Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
    Wojas-Krawczyk K; Kalinka-Warzocha E; Reszka K; Nicoś M; Szumiło J; Mańdziuk S; Szczepaniak K; Kupnicka D; Lewandowski R; Milanowski J; Krawczyk P
    Adv Clin Exp Med; 2019 Jan; 28(1):67-73. PubMed ID: 30085422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.
    Sclafani F; Wilson SH; Cunningham D; Gonzalez De Castro D; Kalaitzaki E; Begum R; Wotherspoon A; Capdevila J; Glimelius B; Roselló S; Thomas J; Tait D; Brown G; Oates J; Chau I
    Int J Cancer; 2020 Jan; 146(1):94-102. PubMed ID: 31199501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing.
    Zou SM; Li WH; Wang WM; Li WB; Shi SS; Ying JM; Lyu N
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2149-2159. PubMed ID: 30171333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study.
    Negru S; Papadopoulou E; Apessos A; Stanculeanu DL; Ciuleanu E; Volovat C; Croitoru A; Kakolyris S; Aravantinos G; Ziras N; Athanasiadis E; Touroutoglou N; Pavlidis N; Kalofonos HP; Nasioulas G
    BMJ Open; 2014 May; 4(5):e004652. PubMed ID: 24859998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases.
    Zhang J; Zheng J; Yang Y; Lu J; Gao J; Lu T; Sun J; Jiang H; Zhu Y; Zheng Y; Liang Z; Liu T
    Sci Rep; 2015 Dec; 5():18678. PubMed ID: 26691448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma.
    Franczak C; Dubouis L; Gilson P; Husson M; Rouyer M; Demange J; Leroux A; Merlin JL; Harlé A
    PLoS One; 2019; 14(2):e0212801. PubMed ID: 30811471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer.
    Reggiani Bonetti L; Barresi V; Bettelli S; Caprera C; Manfredini S; Maiorana A
    Hum Pathol; 2017 Apr; 62():91-98. PubMed ID: 28025078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TaqMan probes as blocking agents for enriched PCR amplification and DNA melting analysis of mutant genes.
    Botezatu IV; Panchuk IO; Stroganova AM; Senderovich AI; Kondratova VN; Shelepov VP; Lichtenstein AV
    Biotechniques; 2017 Feb; 62(2):62-68. PubMed ID: 28193149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.
    Módos O; Reis H; Niedworok C; Rübben H; Szendröi A; Szász MA; Tímár J; Baghy K; Kovalszky I; Golabek T; Chlosta P; Okon K; Peyronnet B; Mathieu R; Shariat SF; Hollósi P; Nyirády P; Szarvas T
    Oncotarget; 2016 Jun; 7(26):39293-39301. PubMed ID: 27283768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients.
    Xu X; Huang F; Cao M; Chen X; Wang H; Jiang H; Yu Y; Shen M; Yang Y; Wang B; Liu T; Guo W
    J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation analysis of CTNNB1 gene and the ras pathway genes KRAS, NRAS, BRAF, and PIK3CA in eyelid sebaceous carcinomas.
    Kwon MJ; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY
    Pathol Res Pract; 2017 Jun; 213(6):654-658. PubMed ID: 28551389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
    Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
    Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of Rare Mutations by Routine Analysis of KRAS, NRAS, and BRAF Oncogenes.
    Mikhailenko DS; Efremov GD; Safronova NY; Strelnikov VV; Alekseev BY
    Bull Exp Biol Med; 2017 Jan; 162(3):375-378. PubMed ID: 28091917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients.
    Guo F; Gong H; Zhao H; Chen J; Zhang Y; Zhang L; Shi X; Zhang A; Jin H; Zhang J; He Y
    Sci Rep; 2018 Apr; 8(1):6076. PubMed ID: 29666387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients.
    Mirzapoor Abbasabadi Z; Hamedi Asl D; Rahmani B; Shahbadori R; Karami S; Peymani A; Taghizadeh S; Samiee Rad F
    J Clin Lab Anal; 2023 Mar; 37(5):e24868. PubMed ID: 36930789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.